[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pseudomyxoma-peritonei\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pseudomyxoma-peritonei":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,76,105,134,163,189,211,241,265],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054012","phase-2-metformin-in-pseudomyxoma-peritonei-secondary-to-appendiceal-mucinous-neoplasms-100054012",false,"NCT07693452","Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms","Use of Metformin in Patients With Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms","Key Inclusion Criteria (complete details available in protocol):\n\n* Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to presumed appendiceal mucinous neoplasms (AMNs) with recurrent\u002Frefractory disease s\u002Fp cytoreductive surgery(CRS)\u002Fhyperthermic intraperitoneal chemotherapy (HIPEC), unresectable disease, or without planned CRS\u002FHIPEC\n* Age ≥18 years\n* ECOG performance status ≤2\n\nKey Exclusion Criteria (complete details available in protocol):\n\n* Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS\u002FHIPEC\n* Patients currently taking metformin for another medical indication\n* Patients with a prior adverse event to administration of metformin","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).",[26,27],"Appendiceal Mucinous Neoplasm","Pseudomyxoma Peritonei",[26,27,29,30,31,32],"Pseudomyxoma Peritoneal","PMP","AMNs","Metformin","RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-06-18",{"date":41,"type":20},"2029-07",{"name":43,"class":44},"University of California, Irvine","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100522604","phase-2-intestinal--multivisceral-transplantation-for-unresectable-mucinous-carcinoma-peritonei-transcape-100522604","NCT06084780","Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)","Prospective Case Series of Intestinal and Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)","TRANSCAPE","Inclusion Criteria:\n\n* Subjects must have histologically confirmed pseudomyxoma peritonei (PMP)\n\n  * Both low-grade mucinous carcinoma peritonei (LMCP) or high-grade mucinous carcinoma (HMCP), with or without signet ring cells as well as primary or recurrent disease, will be eligible.\n* PMP disease does not have any extra-abdominal metastases, with the exception of pulmonary involvement (nodal, parenchymal, and pleural).\n* PMP disease is extensive and not amenable to operative management, with or without liver, pancreas, stomach, or abdominal wall involvement.\n\n  * Definition of Non-Resectable Disease-\n\n    * Non-resectable PMP disease will be defined as the presence of at least one of the following conditions:\n\n      * 1\\) Extensive small bowel serosa involvement, where it is not possible to preserve at least 1.5-2 m of small bowel\n      * 2\\) Extensive infiltration of the pancreatic surface\n      * 3\\) Mesenteric involvement causing retraction\n      * 4\\) Need for complete gastric resection\n      * 5\\) Urete1ic obstruction\n      * 6\\) Liver disease with no chance to achieve R0 resection with liver remnant volume \\> 30%\n      * 7\\) Recurrent disease not amenable to further resection\n* Subjects do not have any other available curative treatment options.\n\n  * Subjects can have previous abdominal operations, including CRS+HIPEC.\n* Age ≥ 18 and ≤ 75.\n\n  * Pediatric participants were excluded as PMP is a disease that affects adults. Participants \\> 75 years of age are excluded as they are beyond the commonly accepted transplantability criteria.\n* Performance status ECOG ≤ 1.\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Subjects with peritoneal carcinomatous originating from an etiology other than PMP.\n* Subjects receiving any other investigational agents.\n* Subjects with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would either put participation at risk because of participation in the study, may influence the result of the study, or limit compliance with study requirements.\n* Pregnant women are excluded from this study because an intestinal transplant is a procedure that is not compatible with a viable pregnancy.\n* Subjects who are HIV-positive may be included in the study. HIV testing is required for the study as adequate HIV treatment is required prior to intestinal transplant due to the increased risk of infection following transplantation and treatment with immunosuppressive agents.","75 Years",{"count":56,"type":20},20,[23],"The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments. Participants will undergo intestinal\u002Fmultivisceral transplantation. Participants will be followed for 12 months to assess efficacy and safety.",[60,61,27],"Secondary Malignant Neoplasm of Retroperitoneum","Secondary Malignant Neoplasm of Peritoneum",[63,64,27,65,52],"Intestinal Transplantation","Multivisceral Transplantation","Unresectable Mucinous Carcinoma Peritonei","NOT_YET_RECRUITING","2026-06-04",{"date":69,"type":37},"2026-06-05",{"date":71,"type":20},"2026-08",{"date":73,"type":20},"2026-12-31",{"name":75,"class":44},"Case Comprehensive Cancer Center",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":45},"100555513","phase-3-study-to-evaluate-the-non-inferiority-of-low-dose-hipec-versus-high-dose-hipec-in-the-treatment-of-pmp-hipec-pmp-100555513","NCT06513065","Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)","A Single Blinded Randomised Controlled Study to Evaluate the Non-inferiority of HIPEC With Mitomycin C 10 mg\u002Fm2 for 60 Minutes Versus HIPEC With Mitomycin C 35mg\u002Fm2 for 90 Minutes in the Treatment of Pseudomyxoma Peritonei From Perforated Epithelial Mucinous Tumours of the Appendix","HIPEC-PMP","Inclusion Criteria:\n\n1. Clinical and\u002For radiological diagnosis of pseudomyxoma peritonei from a primary mucinous epithelial tumours of the appendix (low and high grade)\n2. The extent of intraperitoneal disease must be deemed to be amenable to complete cytoreduction (CC0-1, i.e. residual disease of \\\u003C 2.5mm in diameter).\n3. Patients aged 16 or more and capable of giving informed consent for the procedures and interventions of the current trial.\n4. ECOG performance status 0-1.\n\n   Exclusion Criteria:\n5. Patients who have previously undergone cytoreductive surgery and\u002For intraperitoneal chemotherapy.\n6. Clinical evidence or suspicion of metastases to sites different than peritoneum or intra-abdominal lymph nodes\n7. Hypersensitivity to the active substance (mitomycin) or its excipients (mannitol, hydrochloric acid, sodium hydroxide)\n8. Patients with conditions which may affect their ability to understand, retain and weigh up the information related to the requirements and consenting process of the study\n9. Women who are pregnant or breastfeeding.","16 Years",{"count":86,"type":20},176,[88],"PHASE3","The Investigators are researching how to improve the treatment currently available for patients diagnosed with Pseudomyxoma Peritonei (PMP). This is a rare cancer that usually starts in the appendix and spreads around the abdomen.\n\nPMP is usually treated using a type of surgery called Cytoreductive Surgery (CRS). During the surgery heated chemotherapy will also be used to treat any cancer cells that cannot be seen and may be left behind. This is called Hyperthermic Intraperitoneal Chemotherapy (HIPEC).\n\nThis treatment is commonly used in the UK and in Europe, however, the chemotherapy can be given at two different doses: a lower dose over 60 minutes or a higher-dose over 90 minutes.\n\nThe Investigators want to understand if there is a difference between these two doses. The higher dose has been associated with a slightly increased rate of complications but may be better at killing cancer cells and preventing recurrence of cancer. In Basingstoke the lower dose over 60 minutes is used and survival results are similar to centres who use the higher dose.\n\nPrevious studies have shown that both doses are effective at treating PMP, but no research has shown which is better for patients. The Investigators hope to show that the lower-dose over 60-minutes is as good as the higher-dose over 90-minutes.",[27],[92,93,94,95],"Psuedomyxoma Peritonei","Mitomycin C","Hyperthermic Intraperitoneal Chemotherapy","Appendix","2026-02-17",{"date":98,"type":37},"2026-02-19",{"date":100,"type":37},"2024-12-04",{"date":102,"type":20},"2029-04",{"name":104,"class":44},"University of Southampton",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":45},"100622034","proactive-temperature-management-in-crs-hipec-for-prevention-of-delirium-100622034","NCT07378371","Proactive Temperature Management in CRS-HIPEC for Prevention of Delirium","Proactive Temperature Management and Delirium After Cytoreductive Surgery With HIPEC: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients (aged 18-80 years).\n\nAmerican Society of Anesthesiologists (ASA) physical status of I to III.\n\nScheduled for elective Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Pseudomyxoma Peritonei (PMP).\n\nWritten informed consent obtained from the participant or legally authorized representative.\n\nExclusion Criteria:\n\n* Known diagnosis of dementia, major neurocognitive disorder, or severe psychiatric illness (e.g., schizophrenia) documented in the medical record.\n\nAcute central nervous system pathology likely to confound delirium assessment (e.g., recent stroke, active seizure disorder, or traumatic brain injury).\n\nSevere sensory or language barriers precluding valid cognitive screening (e.g., profound deafness or blindness, or language barriers not correctable with translation).\n\nPreoperative coma, mechanical ventilation, or deep sedation precluding reliable baseline assessment.\n\nEmergency surgery or repeat CRS-HIPEC during the same hospital admission.\n\nHistory of alcohol or substance abuse likely to precipitate withdrawal symptoms.","80 Years",{"count":114,"type":20},174,[116],"NA","This randomized controlled trial evaluates the efficacy of a proactive Goal-Directed Temperature Management (GDTM) protocol in reducing postoperative delirium among patients undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for pseudomyxoma peritonei.\n\nCRS-HIPEC presents a unique physiological challenge characterized by a biphasic thermal trajectory: potential hypothermia during extensive surgery followed by rapid iatrogenic hyperthermia during perfusion. This study compares a standardized GDTM strategy-which incorporates strict normothermia maintenance and anticipatory pre-cooling prior to perfusion-against standard reactive thermal management. The primary objective is to determine if optimized thermoregulation can attenuate thermal variability and improve early neurocognitive recovery.",[27,119],"Postoperative Delirium (POD)",[121,122,94,123,124],"Cytoreductive Surgery","HIPEC","Temperature Management","Goal-Directed Therapy","2026-01-27",{"date":127,"type":37},"2026-01-30",{"date":129,"type":20},"2026-02-01",{"date":131,"type":20},"2026-05-01",{"name":133,"class":44},"Aerospace Center Hospital",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":144,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":45},"100364414","impact-of-cardiac-coherence-on-anxiety-in-patients-operated-on-for-a-peritoneal-carcinosis-100364414","NCT04024917","Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis","Implementation of a Cardiac Coherence Program to Reduce Anxiety in Patients With Peritoneal Carcinosis Treated by Surgery: Randomized Pilot Study","COCOON","Inclusion Criteria:\n\n1. Age over 18 years\n2. Patients with peritoneal carcinosis awaiting cytoreductive surgery\n3. Patients who scored strictly above 3 on the visual analogue anxiety scale and\u002For the psychological distress scale\n4. Patients with sufficient command of the French language\n5. Patient affiliated to a French social security system\n6. Patient hospitalized at the Institute of cancer of Montpellier the day before his cytoreductive surgery (at T1 = D-1)\n7. Signing of informed consent before any specific trial procedure\n\nExclusion Criteria:\n\n1. Patients who already have daily practice of cardiac coherence\n2. Presence of proven psychiatric disorders (e.g., mental retardation, psychotic disorders, learning disabilities, attention deficit\u002Fhyperactivity, bipolar disorder, etc.) other than mood disorders that are reactive to the disease experience, or receiving psychotic treatment that may impair thinking, judgment or discernment\n3. Physical or sensory inability to respond to questionnaires\n4. Patients who have had a heart transplant or bypass surgery in the Year before surgery\n5. Patient with a history of uncontrolled neurological pathology within the last 6 months before inclusion in the trial\n6. Patients with a history of psychoactive substance dependence (excluding smoking) in the last 6 months before inclusion in the trial\n7. Patients with brain metastases\n8. Known natural bradycardia 50 beats per minute\n9. Beta-blocker intake in progress\n10. Ongoing cardiac arrhythmias\n11. Known severe heart failure with ventricular ejection fraction strictly Below 40 %\n12. Chronic uncontrolled pain and making it difficult to practice the technique\n13. Patient with chronic obstructive pulmonary disease\n14. Legal incapacity (patient under guardianship or curatorship)",{"count":143,"type":20},60,[116],"The investigator proposes to use the cardiac coherence technique to diminish anxiety before the surgery of a peritoneal carcinosis of colon or stomach or ovary and pseudomyxoma or peritoneal mesothelioma.",[147,27,148],"Peritoneal Carcinomatosis","Mesothelioma Peritoneum",[150,151,152,153],"Colon","Rectum","Stomach","Ovary","2026-01-15",{"date":156,"type":37},"2026-01-16",{"date":158,"type":37},"2021-09-21",{"date":160,"type":20},"2026-12",{"name":162,"class":44},"Institut du Cancer de Montpellier - Val d'Aurelle",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":21,"phases":172,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":45},"100619187","early-phase-1-pseudovax---a-cancer-vaccine-for-patients-with-pseudomyxoma-peritonei-100619187","NCT07341360","Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei","Pseudovav - A Cancer Vaccine Targeting Mutated GNAS Combined With Immune Checkpoint Inhibition for Patienes With Pseudomyxoma Peritonei","Pseudovax","Inclusion Criteria:\n\n1. The subject is ≥ 18 years of age on the day of signing the informed consent form, able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments.\n2. Confirmed diagnosis of recurrent or non-resectable PMP with no other available treatment options that are expected to be efficacious.\n3. The subject's tumor must carry a mutation in the GNAS oncogene\\*\n4. Subjects must have peritoneal tumor distribution at screening that, in the opinion of the Investigator, is suitable for repeat biopsies: Up to 3 biopsies of target tissue are planned for subjects that complete the study.\n5. Adequate organ, bone marrow, liver, and renal function at screening, including:\n\n   1. Absolute neutrophil count: ≥ 1,5 x109\u002FL\n   2. Platelets: ≥ 100 x109\u002FL\n   3. Hemoglobin: ≥ 9 x109\u002FL\n   4. Creatinine ≤ 1,5 upper limit normal (ULN) OR measured\u002Fcalculated GFR ≥60 mL\u002Fmin\n   5. Albumin ≥ 30 g\u002FL\n   6. Total bilirubin ≤ 1,5 ULN\n   7. ASAT and ALAT ≤ 3 ULN\n   8. International Normalized Ratio (INR) ≤ 1,5 ULN and Activated Partial Thromboplastin Time (aPTT) ≤ 1,5 ULN unless subject is receiving anticoagulant therapy.\n6. ECOG performance status of 0 or 1.\n7. Life expectancy of \\>6 months, at the time of signing the informed consent.\n8. Women of childbearing potential must have a negative serum pregnancy test within 48 hours of the first study intervention, and must not be breast-feeding. 8ai. Female participant:\n\n   i. Unless documented not to have childbearing potential: Subject is willing to use contraceptive measures for the duration of the study, and ≥ 6 months after the last dose of IMP, as prescribed by the protocol (according to the applicable guidance: CTFG, 2020). The Investigator should counsel women of childbearing potential of the importance of pregnancy prevention.\n\n8aii. Women of childbearing potential must have a negative serum pregnancy test within 48 hours of the first study intervention.\n\n8b. Male subject: Sexually active males must be willing to use a condom during sex for the duration of the study and for ≥ 6 months after the last dose of IMP. Males must also be willing to abstain from donating sperm during the same period.\n\nExclusion Criteria:\n\n1. Patient has Eastern Cooperative Oncology Group performance status 2 or worse.\n2. Blood transfusion or growth factor support ≤ 14 days before sample collection at screening.\n3. Active malignancy the past 3 years except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast)\n4. Enrollment in another interventional trial that, in the opinion of the Investigator, could influence the outcome of this study.\n5. Subject has within the last 30 days received any other interventional therapy that, in the opinion of the Investigator, could influence the outcome of this study.\n6. Pregnancy or lactating female.\n7. Known active hepatitis B or C, or is known to be HIV-positive.\n8. Any condition that required systemic treatment with either corticosteroids (\\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of IMP.\n\n   Note: Subjects who are currently or have previously been on any of the following steroid regimens are not excluded: Adrenal replacement steroid (dose ≤ 10 mg daily of prednisone or equivalent); Topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption; Short course (≤ 7 days) of corticosteroid prescribed prophylactically (e.g., for contrast dye allergy) or for the treatment of a non-autoimmune condition (e.g., delayed-type hypersensitivity reaction caused by contact allergen).\n9. Active autoimmune diseases or history of autoimmune diseases that may relapse. Note: Subjects with the following diseases are not excluded and may proceed to further screening, controlled Type I diabetes, hypothyroidism (provided it is managed with hormone replacement therapy only), controlled celiac disease skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, alopecia), any other disease that is not expected to recur in the absence of external triggering factors.\n10. Diagnosis of immunodeficiency.\n11. History of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc.\n12. Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection, etc.\n13. Severe infections within 4 weeks before first dose of IMP, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.\n14. Therapeutic oral or intravenous antibiotics within 2 weeks before first dose of IMP.\n15. Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of IMP.\n16. Prior allogeneic stem cell transplantation or organ transplantation\n17. Cardiac chest pain, defined as moderate pain that limits instrumental activities of daily living, ≤ 28 days before first dose of IMP.\n18. Pulmonary embolism ≤ 28 days before first dose of IMP.\n19. History of acute myocardial infarction ≤ 6 months before first dose of IMP.\n20. History of heart failure meeting New York Heart Association (NYHA) Classification III or IV (Appendix 6) ≤ 6 months before first dose of IMP.\n21. Subject has had any event of ventricular arrhythmia ≥ Grade 2 in severity ≤ 6 months before first dose of IMP.\n22. Severe hypersensitivity (≥grade 3) to chemotherapy, any other biologic drug or the contents or preservatives of any of the study drugs.\n23. History of cerebrovascular accident ≤ 6 months before first dose of IMP.\n24. Subject has underlying medical conditions (including laboratory abnormalities) or alcohol or drug abuse or dependence that, will be unfavorable for the administration of study drug or affect the explanation of drug toxicity or AEs or result in insufficient or might impair compliance with study conduct.\n25. Any reason why, in the opinion of the investigator, the patient should not participate.",{"count":5,"type":20},[173],"EARLY_PHASE1","Participants will receive vaccination with Pseudovax\u002FGM-CSF in combination with PD-1 inhibitor tislelizumab over a period of up to two years. The vaccine is expected to reactivate measurable immune response, and tislelizumab to restore anticancer immunity in patients with GNAS mutated pseudomyxoma peritonei.",[27],[169,30,177,178,179],"Peptide vaccine","GNAS mutation","pseudomyxoma peritonei","2026-01-07",{"date":182,"type":37},"2026-01-14",{"date":184,"type":37},"2025-10-13",{"date":186,"type":20},"2034-12-31",{"name":188,"class":44},"Oslo University Hospital",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":45},"100618216","one-vs-three-hipec-cycles-after-crs-for-pseudomyxoma-peritonei-100618216","NCT07328737","One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei","Efficacy and Safety of One vs Three Cycles of Hyperthermic Intraperitoneal Chemotherapy After Cytoreductive Surgery for Pseudomyxoma Peritonei: A Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n1. Voluntarily consent to participate, sign informed consent, and be willing and able to comply with the study protocol;\n2. Age 18-70 years;\n3. Undergo CRS+HIPEC with pathological diagnosis of PMP of high grade with signet-ring cells, high grade, or low grade;\n4. Karnofsky performance status (KPS) \\>60;\n5. Adequate function of major organs as follows:\n\n   1. Hematology: WBC ≥3.5×10\\^9\u002FL, ANC ≥1.0×10\\^9\u002FL, LC ≥0.5×10\\^9\u002FL, PLT ≥80×10\\^9\u002FL, Hb ≥90 g\u002FL;\n   2. Hepatic function: AST, ALT, and TBIL ≤2×upper limit of normal (ULN);\n   3. Renal function: serum creatinine \\\u003C1.2×ULN;\n   4. Coagulation: APTT ≤1.5×ULN; INR or PT ≤1.5×ULN;\n   5. Cardiopulmonary function sufficient to tolerate major surgery and HIPEC;\n\n(5) Radiological Peritoneal Cancer Index (PCI) ≥15; (6) No local or systemic antitumor therapy within 1 month prior to CRS+HIPEC; (7) Adverse reactions from prior treatments have resolved before study initiation or, in the investigator's judgment, will not interfere with this study;\n\nExclusion Criteria:\n\n1. Metastases to lung, brain, bone, or liver;\n2. AST, ALT, or TBIL ≥2×ULN;\n3. Serum creatinine ≥1.2×ULN;\n4. Severe mesenteric contraction;\n5. Major organ dysfunction that cannot support the planned procedures;\n6. Concomitant hematological disorders or other malignancies;\n7. Acute or subacute infectious disease;\n8. History of allergy to cisplatin or docetaxel, or marked allergic diathesis or severe allergy history;\n9. Psychiatric or psychological disorders preventing cooperation with treatment and efficacy evaluation;\n10. Any other condition deemed unsuitable for enrollment by the investigator;","70 Years",{"count":198,"type":20},132,[116],"The goal of this clinical trial is to compare the efficacy and safety of one versus three sessions of hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) for patients with pseudomyxoma peritonei (PMP).\n\nThe main questions it aims to answer are:\n\n* Does receiving three HIPEC sessions lead to better Progression-Free Survival (PFS) and Overall Survival (OS) compared to one session?\n* What are the differences in postoperative complications (e.g., infection, bowel obstruction, myelosuppression) and organ toxicity (e.g., liver\u002Fkidney injury) between the two regimens?\n* How do the different treatment schedules impact patients' quality of life?\n\nResearchers will compare the experimental group (3 HIPEC sessions) to the control group (1 HIPEC session) to investigate the efficacy and safety of the additional sessions.\n\nParticipants will:\n\n* Be randomly assigned to one of two groups:\n\n  1. Control Group: Receive only a single intraoperative HIPEC session following CRS.\n  2. Experimental Group: Receive two additional HIPEC sessions after CRS+HIPEC (on post-operative day 2 and day 4) at reduced drug doses.\n* Undergo scheduled safety checks for side effects on days 1, 3, 5, 7, and 10 post-HIPEC.\n* Attend a follow-up visit at 1 month after CRS+HIPEC and, if eligible, receive 6 cycles of standard postoperative chemotherapy.\n* Attend regular long-term follow-up visits for several years, which will include physical examinations, blood tests (for tumor markers), CT scans, and quality-of-life questionnaires (EORTC QLQ-C30 version 3.0).",[27],"2025-12-28",{"date":204,"type":37},"2026-01-09",{"date":206,"type":37},"2025-11-01",{"date":208,"type":20},"2030-11-01",{"name":210,"class":44},"Beijing Tsinghua Chang Gung Hospital",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":222,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":45},"100577599","phase-2-metronomic-neoadjuvant-capecitabine-and-cyclophosphamide-in-huge-pseudomyxoma-peritonei-patients-100577599","NCT06800391","Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients","Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in Huge (PCI>28) Pseudomyxoma Peritonei Patients Candidates to Cytoreductive Surgery (CRS) and Hypertermic Intraperitoneal Chemotherapy (HIPEC)","REVERSE","Inclusion Criteria:\n\n* Clinical\u002FHistological diagnosis of pseudomyxoma peritonei (PMP);\n* Peritoneal Cancer Index (PCI \\>28) assessed by chest and abdominal CT scan at the staging phase;\n* Age \\>= 18 years and \\\u003C76 years;\n* Performance Status (ECOG \\\u003C2);\n* Adequate organ function including the following:\n* Adequate bone marrow reserve: WBC count \\>3.0x109\u002FL, absolute neutrophyl count \\>1.5x109\u002FL, platelet count \\>100x109\u002FL, and hemoglobin \\>10 g\u002FdL;\n* Hepatic: bilirubin \\\u003C 1.5 times the ULN, alkaline phosphatase, aspartate transaminase, and alanine transaminase \\\u003C 2.5 x UL;\n* Renal: Creatinine clearance \\>50 mL\u002Fmin or serum creatinine \\\u003C1.5 x UNL;\n* Patients compliance and geographic proximity that allows for adequate follow-up;\n* Patients must sign an informed consent document (ICD);\n* Male and female patients with reproductive potential must use an approved contraceptive method;\n\nExclusion Criteria:\n\n* Peritoneal Cancer Index (PCI ≤28) assessed by chest and abdominal CT scan at the staging phase;\n* DPD deficiency;\n* Previous systemic chemotherapy and\u002For biological therapy;\n* Administration of other experimental drugs during the study Pregnancy and breast-feeding;\n* Serious or uncontrolled medical pathologies or active infections that would jeopardize the possibility of receiving the investigated treatment;\n* Disorders that could influence the absorption of capecitabine (e.g. malabsorption), intestinal occlusion, Crohn's disease or ulcerative colitis;\n* Psychiatric disorders, neurologic disease or other conditions that would make it impossible to comply with the protocol procedures;\n* Positive anamnesis with regard to other neoplastic diseases except for the ones that have been cured for more than 5 years.","76 Years",{"count":221,"type":20},31,[23],"The goal of this clinical trial is to evaluate the safety and efficacy of neoadjuvant capecitabine and cyclophosphamide treatment in patients affected by huge Pseudomyxoma peritonei (PMP) (peritoneal cancer index \\>28). Treatment consists of metronomic (low-dose medication for a prolonged time) of capecitabine plus cyclophosphamide for 6 months followed by standard of care cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The main question the trial aims to answer is which is the proportion of patients with complete cytoreduction at CRS\u002FHIPEC after neoadjuvant metronomic approach with oral capecitabine and cyclophosphamide in patients affected by huge PMP.",[27],[226,227,228,229,230,122,231],"Pseudomyxoma peritonei","metronomic regimen","capecitabine","cyclophosphamide","cytoreductive surgery","peritoneal cancer index","2025-01-23",{"date":234,"type":37},"2025-01-30",{"date":236,"type":37},"2024-11-22",{"date":238,"type":20},"2029-11",{"name":240,"class":44},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":122,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":250,"phases":4,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":45},"100179987","register-with-patients-in-which-hyperthermic-intra-peritoneal-chemotherapy-hipec-was-performed-100179987","NCT01617382","Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed","Register With Data From Patients With the Diagnosis of a Peritoneal Surface Malignancy, for Which Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) is Performed","Inclusion Criteria:\n\n* Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy",{"count":249,"type":20},125,"OBSERVATIONAL","The purpose of this study is to register the follow-up data of patients who, because of a peritoneal surface malignancy, will undergo cytoreductive surgery and HIPEC.",[147,27,253],"Peritoneal Mesothelioma",[122,255],"Hyperthermic (heated) chemotherapy after debulking","2024-06-25",{"date":258,"type":37},"2024-06-26",{"date":260,"type":4},"2012-05",{"date":262,"type":20},"2028-12",{"name":264,"class":44},"Universitaire Ziekenhuizen KU Leuven",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":273,"targetDuration":275,"studyType":250,"phases":4,"briefSummary":276,"conditions":277,"keywords":281,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":45},"100214809","peritoneal-surface-malignancies---characterization-models-and-treatment-strategies-100214809","NCT02073500","Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies","Prospective Observational Study of Peritoneal Surface Malignancies (PSM) - Characterization, Models and Treatment Strategies.","PSM","Inclusion Criteria:\n\n* age \\> 18 years\n* confirmed diagnosis of peritoneal surface malignancy\n* candidate for CRS-HIPEC\n* written informed consent\n\nExclusion Criteria:\n\n* none\n\nApproximately 80 patients per year will be eligible for inclusion, as this is the number of patients that annually receive surgical treatment for PSM.",{"count":274,"type":20},300,"5 Years","The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).",[27,278,279,280],"Colorectal Carcinoma","Ovarian Carcinoma","Mesothelioma",[282,283,284,285,286,122,287,288],"Peritoneal carcinomatosis","Peritoneal surface malignancy","Cytoreductive surgery","Hyperthermic intraperitoneal chemotherapy","CRS","Prognostic biomarker","Predictive biomarker","2021-07-21",{"date":291,"type":37},"2021-07-28",{"date":293,"type":37},"2009-09",{"date":295,"type":20},"2027-08",{"name":188,"class":44}]